Quest Partners LLC Raises Stake in AxoGen, Inc. (NASDAQ:AXGN)

Quest Partners LLC raised its position in AxoGen, Inc. (NASDAQ:AXGN) by 23,066.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,085 shares of the medical equipment provider’s stock after acquiring an additional 2,076 shares during the quarter. Quest Partners LLC’s holdings in AxoGen were worth $29,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. nVerses Capital LLC purchased a new position in AxoGen in the third quarter worth approximately $56,000. Koss Olinger Consulting LLC purchased a new stake in shares of AxoGen during the 2nd quarter worth approximately $75,000. Lazard Asset Management LLC lifted its position in shares of AxoGen by 30.1% during the 1st quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock worth $93,000 after buying an additional 2,671 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of AxoGen during the 2nd quarter worth approximately $125,000. Finally, Oppenheimer & Co. Inc. purchased a new stake in shares of AxoGen during the 3rd quarter worth approximately $156,000. Hedge funds and other institutional investors own 80.29% of the company’s stock.

AxoGen Stock Down 1.2 %

AXGN stock opened at $13.90 on Monday. The company has a fifty day moving average price of $13.68 and a 200 day moving average price of $10.88. AxoGen, Inc. has a 12 month low of $5.55 and a 12 month high of $15.90. The company has a market cap of $611.74 million, a price-to-earnings ratio of -43.44 and a beta of 1.13. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. StockNews.com upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. JMP Securities boosted their price objective on shares of AxoGen from $17.00 to $20.00 and gave the stock a “market outperform” rating in a research report on Friday, August 9th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $15.00.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.